GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Intrinsic Value: Projected FCF

Cardiovascular Systems (Cardiovascular Systems) Intrinsic Value: Projected FCF : $3.42 (As of Apr. 26, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-26), Cardiovascular Systems's Intrinsic Value: Projected FCF is $3.42. The stock price of Cardiovascular Systems is $20.00. Therefore, Cardiovascular Systems's Price-to-Intrinsic-Value-Projected-FCF of today is 5.9.

The historical rank and industry rank for Cardiovascular Systems's Intrinsic Value: Projected FCF or its related term are showing as below:

CSII' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 3.59   Med: 7.84   Max: 12.49
Current: 5.85

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Cardiovascular Systems was 12.49. The lowest was 3.59. And the median was 7.84.

CSII's Price-to-Projected-FCF is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.65 vs CSII: 5.85

Cardiovascular Systems Intrinsic Value: Projected FCF Historical Data

The historical data trend for Cardiovascular Systems's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems Intrinsic Value: Projected FCF Chart

Cardiovascular Systems Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.66 -0.64 2.72 4.25 4.00

Cardiovascular Systems Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.26 4.55 4.00 3.60 3.42

Competitive Comparison of Cardiovascular Systems's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Cardiovascular Systems's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiovascular Systems's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Cardiovascular Systems's Price-to-Projected-FCF falls into.



Cardiovascular Systems Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Cardiovascular Systems's Free Cash Flow(6 year avg) = $-5.85.

Cardiovascular Systems's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec22)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-5.84944+239.389*0.8)/39.664
=3.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiovascular Systems  (NAS:CSII) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Cardiovascular Systems's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=20.00/3.4243262041272
=5.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiovascular Systems Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiovascular Systems (Cardiovascular Systems) Business Description

Traded in Other Exchanges
N/A
Address
1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.
Executives
Jeffrey S. Points officer: Chief Financial Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward director RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb officer: Chief Operating Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson director 40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein officer: General Counsel & Corp. Secy C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo officer: Chief Compliance Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe officer: Chief Human Resources Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings officer: VP Manufacturing & Operations C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland officer: VP of Medical Affairs C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver officer: VP of Corp. Dev. & IP C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund officer: Chief Talent Officer

Cardiovascular Systems (Cardiovascular Systems) Headlines

From GuruFocus